Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 145 | $87,909,483 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
12 Jan 2024 18:02 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Jan 2024 | Sale | 1,486 | 67.8 | 100,751 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,400 | 70.16 | 98,224 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,400 | 69.38 | 97,132 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 26 Feb 2024 | Sale | 1,312 | 71.02 | 93,178 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 1,307 | 71.18 | 93,032 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 11 Mar 2024 | Sale | 1,313 | 66.86 | 87,787 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 17 Feb 2023 | Sale | 1,689 | 50.59 | 85,447 | D |
12 Aug 2022 18:09 | ITCI | Intra-Cellular Therapies Inc | VAN NOSTRAND ROBERT L | Director | 11 Aug 2022 | Sale | 1,500 | 56.8 | 85,200 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 11 Mar 2024 | Sale | 1,238 | 66.7 | 82,575 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 10 Mar 2023 | Sale | 1,800 | 42.74 | 76,932 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 1,100 | 66.54 | 73,194 | D |
13 Mar 2023 19:31 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 13 Mar 2023 | Sale | 1,412 | 44.08 | 62,241 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 872 | 65.89 | 57,456 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 1,100 | 48.68 | 53,548 | D |
05 Feb 2024 18:13 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 02 Feb 2024 | Sale | 714 | 67.17 | 47,959 | D |
11 Mar 2024 20:31 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 11 Mar 2024 | Sale | 661 | 66.96 | 44,261 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 900 | 48.72 | 43,848 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 600 | 69.81 | 41,886 | D |
27 Feb 2024 19:59 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 26 Feb 2024 | Sale | 600 | 68.39 | 41,034 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 806 | 48.63 | 39,196 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 800 | 47.32 | 37,856 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 800 | 47.2 | 37,760 | D |
22 Feb 2023 20:05 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 21 Feb 2023 | Sale | 635 | 48.93 | 31,071 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 643 | 47.23 | 30,369 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 392 | 70.13 | 27,491 | D |
18 Jan 2024 19:47 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 18 Jan 2024 | Sale | 320 | 66.25 | 21,200 | D |
13 Mar 2023 19:34 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 13 Mar 2023 | Sale | 476 | 44.15 | 21,015 | D |
27 Feb 2024 19:57 | ITCI | Intra-Cellular Therapies Inc | MARCUS JOEL S | Director | 26 Feb 2024 | Sale | 299 | 69.6 | 20,810 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 11 Mar 2024 | Sale | 306 | 67.33 | 20,603 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 26 Feb 2024 | Sale | 300 | 68.54 | 20,562 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 300 | 68.33 | 20,499 | D |
27 Feb 2024 20:00 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 26 Feb 2024 | Sale | 288 | 70.15 | 20,203 | D |
13 Mar 2023 19:35 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 13 Mar 2023 | Sale | 423 | 44.05 | 18,633 | D |
13 Mar 2023 19:36 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | EVP, Chief Medical Officer | 13 Mar 2023 | Sale | 346 | 44.29 | 15,324 | D |
11 Mar 2024 20:32 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 07 Mar 2024 | Sale | 220 | 66.81 | 14,698 | D |
27 Feb 2024 19:58 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 26 Feb 2024 | Sale | 200 | 68.03 | 13,606 | D |
05 Feb 2024 18:05 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 02 Feb 2024 | Sale | 185 | 67.35 | 12,460 | D |
22 Feb 2023 20:01 | ITCI | Intra-Cellular Therapies Inc | MATES SHARON | Chairman, President & CEO | 21 Feb 2023 | Sale | 251 | 49.6 | 12,450 | D |
13 Mar 2023 19:32 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 13 Mar 2023 | Sale | 258 | 44.14 | 11,388 | D |
22 Feb 2023 20:05 | ITCI | Intra-Cellular Therapies Inc | NEUMANN MARK | EVP, Chief Commercial Officer | 21 Feb 2023 | Sale | 123 | 47.32 | 5,820 | D |
22 Feb 2023 20:03 | ITCI | Intra-Cellular Therapies Inc | HALSTEAD MICHAEL | EVP and General Counsel | 21 Feb 2023 | Sale | 100 | 49.6 | 4,960 | D |
22 Feb 2023 20:02 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance CFO | 21 Feb 2023 | Sale | 94 | 49.6 | 4,662 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 64 | 67.12 | 4,296 | D |
22 Feb 2023 20:04 | ITCI | Intra-Cellular Therapies Inc | DURGAM SURESH K. | SVP, Chief Medical Officer | 21 Feb 2023 | Sale | 75 | 49.6 | 3,720 | D |
11 Mar 2024 20:33 | ITCI | Intra-Cellular Therapies Inc | HINELINE LAWRENCE J. | SVP of Finance, CFO | 11 Mar 2024 | Sale | 29 | 67.32 | 1,952 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)